Device for Ocular Drug Delivery

Back to all technologies
Download as PDF
Ocular drug delivery is very challenging due to the complex and sensitive structure of the eye. Researchers at Purdue University have developed a minimally invasive and effective ocular drug delivery platform. This method enables long term sustained release of therapeutic ocular drugs via a tear-soluble contact lens that leaves behind biodegradable silicon nanoneedles. The tear-soluble contact lens provides an optimal curvature to fit the cornea and it is degraded in less than a minute, enabling initial short-term release of anti-inflammatory drugs and long-term release of therapeutic drugs. This technology directly benefits patients undergoing treatment for chronic diseases or injuries, including glaucoma, cataract, and graft rejection.


Minimally invasive

- Long term sustained release

- Initial burst release of anti-inflammatory

- Long-term release of therapeutic drugs

- Demonstrated biosafety and efficacy in lab testing


- Ocular drug delivery

- Treatments for glaucoma, cataract, and graft rejection

Technology Validation:
This technology has been validated for efficacy and safety through successful in vivo testing in a rabbit corneal neovascularization (CNV) model.
Oct 10, 2022
PCT-Gov. Funding

Oct 8, 2021
Provisional-Gov. Funding
United States
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486